SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001347178-20-000030
Filing Date
2020-10-29
Accepted
2020-10-29 07:01:12
Documents
75
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20200930.htm   iXBRL 10-Q 1305463
2 EX-31.1 vndaex311930202010q.htm EX-31.1 10535
3 EX-31.2 vndaex312930202010q.htm EX-31.2 10208
4 EX-32.1 vndaex321930202010q.htm EX-32.1 6728
  Complete submission text file 0001347178-20-000030.txt   5839526

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20200930.xsd EX-101.SCH 46008
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20200930_cal.xml EX-101.CAL 81316
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20200930_def.xml EX-101.DEF 203633
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20200930_lab.xml EX-101.LAB 517172
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20200930_pre.xml EX-101.PRE 347761
10 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20200930_htm.xml XML 947150
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 201270436
SIC: 2834 Pharmaceutical Preparations